Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 87, Issue 1, Pages 130-133Publisher
WILEY
DOI: 10.1038/clpt.2009.197
Keywords
-
Categories
Funding
- Helsinki University Central Hospital Research Fund (Helsinki, Finland)
- Sigrid Juselius Foundation (Helsinki, Finland)
Ask authors/readers for more resources
Polymorphisms in transporter genes can have profound effects on statin pharmacokinetics. In particular, a common genetic variant of organic anion-transporting polypeptide 1B1 reduces the hepatic uptake of many statins, increasing the risk of statin-induced myopathy. Similarly, genetically impaired adenosine triphosphate (ATP)-binding cassette G2 transporter efflux activity results in a marked increase in systemic exposure to various statins. Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid-lowering therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available